TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX)

Q: What does CUSIP 89854M101 represent in this 13F holders report?

CUSIP 89854M101 is the security identifier for TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share in Q2 2025?

79 institutional investors reported TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share for Q2 2025. Use the holders table for investor-level position and value details.

CUSIP: 89854M101

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Voting Common Stock, par value $0.0001 per share
Shares outstanding: 52,382,313
Total 13F shares: 35,724,879
Share change: -4,382,817
Total reported value: $51,820,655
Price per share: $1.45
Number of holders: 79
Value change: -$5,881,550
Number of buys: 46
Number of sells: 49

Quarterly Holders Quick Answers

What is CUSIP 89854M101?
CUSIP 89854M101 identifies TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 89854M101:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
EcoR1 Capital, LLC	3/4/5 13D/G 13F	10%+ Owner · Company	1.3% from 13D/G	5,000,000	$24,842,500	—	26 May 2023	3/4/5 13D/G 13F
Lynx1 Capital Management LP	13D/G 13F	Company	15%	7,857,347	$11,393,153	+$3,625,000	30 Jun 2025	13D/G 13F
Christoph H. Westphal	3/4/5	10%+ Owner	— class O/S missing	2,193,472	$10,898,266	—	20 Jul 2021	3/4/5
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	10%	5,263,541	$8,421,666	$0	31 Mar 2025	13D/G
BVF INC/IL	13F	Company	9.3%	4,889,474	$6,747,474	—	31 Mar 2025	13F
BlackRock, Inc.	13F 13D/G	Company	1.8% from 13D/G	4,878,833	$6,732,789	—	31 Mar 2025	13F 13D/G
K2 HealthVentures Equity Trust LLC	13D/G	—	6.9%	3,602,700	$5,764,320	$0	31 Dec 2024	13D/G
ADAGE CAPITAL PARTNERS GP, L.L.C.	13D/G 13F	Adage Capital Management, L.P. · Company	7.1%	3,500,000	$5,600,000	$0	31 Dec 2024	13D/G 13F
BAKER BROS. ADVISORS LP	13F 3/4/5	Company · Director	5.3%	2,784,792	$3,843,013	—	31 Mar 2025	13F 3/4/5
VANGUARD GROUP INC	13F	Company	4.5%	2,356,746	$3,252,310	—	31 Mar 2025	13F
Propel Bio Management, LLC	13F	Company	4%	2,087,139	$2,880,252	—	31 Mar 2025	13F
Checkpoint Capital L.P.	13F	Company	3.9%	2,017,650	$2,784,357	—	31 Mar 2025	13F
Adage Capital Management, L.P.	13D/G	—	2.5%	1,350,000	$1,957,500	$0	30 Jun 2025	13D/G
Deer Management Co. LLC	13F	Company	2.4%	1,245,504	$1,718,796	—	31 Mar 2025	13F
Alphabet Inc.	13F	Company	2.1%	1,077,080	$1,486,370	—	31 Mar 2025	13F
Simplify Asset Management Inc.	13F	Company	2%	1,046,916	$1,444,744	—	31 Mar 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.9%	1,015,090	$1,401,161	—	31 Mar 2025	13F
Aberdeen Group plc	13F	Company	1.7%	891,448	$1,230,198	—	31 Mar 2025	13F
STATE STREET CORP	13F	Company	1.6%	817,248	$1,127,802	—	31 Mar 2025	13F
DC Funds, LP	13F	Company	1.2%	630,000	$869,400	—	31 Mar 2025	13F
TANG CAPITAL MANAGEMENT LLC	13F	Company	1.1%	600,000	$828,000	—	31 Mar 2025	13F
MORGAN STANLEY	13F	Company	1.1%	592,970	$818,298	—	31 Mar 2025	13F
Timothy J. Barberich	3/4/5	Director	— mixed-class rows	135,286 mixed-class rows	$498,271	—	18 Dec 2023	3/4/5
NORTHERN TRUST CORP	13F	Company	0.63%	330,024	$455,434	—	31 Mar 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.52%	270,099	$372,663	—	31 Mar 2025	13F
Barbara Klencke	3/4/5	Director	— mixed-class rows	137,000 mixed-class rows	$370,300	—	30 Jun 2025	3/4/5
JPMORGAN CHASE & CO	13F	Company	0.51%	265,101	$365,839	—	31 Mar 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.44%	231,175	$319,022	—	31 Mar 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.33%	170,350	$235,084	—	31 Mar 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.33%	170,349	$235,081	—	31 Mar 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.32%	169,706	$234,194	—	31 Mar 2025	13F
BROWN BROTHERS HARRIMAN & CO	13F	Company	0.27%	143,051	$197,410	—	31 Mar 2025	13F
UBS Group AG	13F	Company	0.24%	123,441	$170,349	—	31 Mar 2025	13F
STIFEL FINANCIAL CORP	13F	Company	0.22%	116,452	$160,704	—	31 Mar 2025	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.22%	113,300	$156,354	—	31 Mar 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.22%	112,941	$155,859	—	31 Mar 2025	13F
NewEdge Wealth, LLC	13F	Company	0.17%	91,463	$126,219	—	31 Mar 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.17%	90,201	$124,477	—	31 Mar 2025	13F
Bank of New York Mellon Corp	13F	Company	0.17%	88,142	$121,636	—	31 Mar 2025	13F
Troluce Capital Advisors LLC	13F	Company	0.16%	83,758	$115,586	—	31 Mar 2025	13F
LETKO, BROSSEAU & ASSOCIATES INC	13F	Company	0.15%	77,100	$106,398	—	31 Mar 2025	13F
Nuveen, LLC	13F	Company	0.13%	69,962	$96,548	—	31 Mar 2025	13F
BARCLAYS PLC	13F	Company	0.12%	61,850	$85,352	—	31 Mar 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.1%	54,392	$75,061	—	31 Mar 2025	13F
DEUTSCHE BANK AG\	13F	Company	0.1%	52,559	$72,532	—	31 Mar 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.1%	51,841	$71,541	—	31 Mar 2025	13F
RHUMBLINE ADVISERS	13F	Company	0.1%	50,019	$69,017	—	31 Mar 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.09%	49,000	$67,620	—	31 Mar 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.09%	48,603	$67,072	—	31 Mar 2025	13F
Pale Fire Capital SE	13F	Company	0.09%	47,734	$65,873	—	31 Mar 2025	13F

Institutional Holders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) as of Q2 2025

As of 30 Jun 2025, TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) was held by 79 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 35,724,879 shares. The largest 10 holders included Lynx1 Capital Management LP, BVF INC/IL, BAKER BROS. ADVISORS LP, BlackRock, Inc., VANGUARD GROUP INC, Propel Bio Management, LLC, Deer Management Co. LLC, Alphabet Inc., Simplify Asset Management Inc., and Aberdeen Group plc. This page lists 79 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

Q2 2025 holders

Holder diff

-13

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.